CGTX - Results from Cognition Therapeutics' Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease Accepted for Presentation at AAIC | Benzinga
PURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that abstracts summarizing clinical efficacy, safety and biomarker findings from the Phase 2 COG0201 "SHINE" study of CT1812 have been accepted for poster presentation at the upcoming Alzheimer's Association's International Conference being held in Philadelphia, PA from July 28-August 1, 2024.
AAIC Presentation details
- Abstract #89115: Clinical Efficacy Results from COG0201: a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Adults with Mild-to-Moderate Alzheimer's Disease
- Abstract #95147: CSF Phosphoproteomics Biomarker Analysis from the Phase 2 Clinical Trial SHINE to Elucidate the Role of CT1812 in Alzheimer's Disease
- Abstract #95767: Topline CSF Biomarker Outcomes from the Phase 2 Clinical Trial SHINE in Alzheimer's Patients
- Abstract #95770: Exploratory CSF Proteomics Biomarker Outcomes of the Phase 2 Clinical Trial Shine to Assess the Effects of CT1812 in Alzheimer's Patients
The company will also host a booth (#731) in the Exhibit Hall during the conference where more information about the company's Alzheimer's disease program and lead candidate CT1812 will be available.
About the SHINE Study
The SHINE study is a double-blind, placebo-controlled Phase 2 clinical trial designed to enroll approximately 144 patients with mild-to-moderate Alzheimer's disease. Participants were evenly randomized to receive either placebo or one of two doses of CT1812 (100 mg or 300 mg), which was taken orally daily for six months. Endpoints include safety, cognitive function as measured by the ADAS-Cog 11, a globally recognized cognitive scale, and biomarker evidence of disease modification. The SHINE study was supported by two grant awards from the National Institute on Aging of the National Institutes of Health (NIH) totaling approximately $30 million.
About CT1812
CT1812 is an experimental orally delivered small molecule that penetrates the blood-brain barrier and binds selectively to the sigma-2 (?-2) receptor complex. Preclinical and clinical data demonstrate that this binding results in the displacement of toxic A? oligomers. The ?-2 receptor complex is involved in the regulation of key cellular processes such as membrane trafficking and autophagy that are damaged by toxic interaction with A? oligomers, oxidative stress and other stressors. This damage to sensitive synapses can progress ...